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Abstract: The aim of this paper is to evaluate the role of apoptosis in some common liver diseases, and the utility of M30, an apoptotic
serum marker, in the diagnosis of the severity of underlying hepatic injury. As is widely known, apoptosis is programmed cell death, and
its deregulation results in an uncontrolled inflammatory process leading to upregulation of liver fibrogenesis. Both extrinsic and intrinsic
pathways are crucial in apoptosis, and caspase cleavage of cytokeratin proteins occurs in both. Therefore, the measurement of caspasecleaved cytokeratin fragments could be a novel method to assess the intensity of apoptotic cell numbers in epithelial tissue damage. M30
levels were found to increase not only in acute liver disorders, but also in some chronic liver injuries. We tried to summarize the recent
studies focused on the role of apoptotic processes in liver diseases, mainly those that investigated the use of M30 in determining the
severity of, or in predicting, ongoing liver injury.
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1. Introduction
Apoptosis, also known as programmed cell death, is a
routine feature of healthy organs and tissues. However,
apoptosis has become an emerging topic of interest in
some acute and chronic liver diseases in the recent years
(1). Apoptosis has been found to be crucial in viral
hepatitis, alcoholic and nonalcoholic steatohepatitis,
cholestatic processes, and Wilson disease (2). It appears
that dysregulated apoptosis has an important role in
inflammation, and also in fibrogenesis (3). While the
number of apoptotic cells should be equal to the number
of newly formed ones, upregulation of apoptosis alters
this healthy homeostasis. The most important part of
apoptosis is that physiological apoptosis does not induce
proinflammatory cytokine secretion, whereas upregulation
does (4). With an increasing apoptosis rate, there may also
be a regeneration stimulus that could also contribute to a
high cancer risk (5).
2. The link from apoptosis to hepatic fibrosis
Apoptotic bodies in the liver can be phagocytosed by
both Kupffer cells and hepatic stellate cells (6,7). After
engulfment of apoptotic bodies by Kupffer cells, the
Kupffer cells express death ligands (tumor necrosis factor
alpha, TNF-α; tumor necrosis factor-related apoptosisinducing ligand, TRAIL; and Fas ligand, FasL), leading
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to a proinflammatory status (7). These death ligands
are closely related with their receptors to hepatocyteinduced death receptor-mediated apoptosis. In massive
liver injury, the apoptotic cell phagocytosis capacity of
Kupffer cells is overwhelmed by the increase in apoptotic
cell engulfment by hepatic stellate cells or myofibroblasts
derived from hepatic stellate cells (8). Myofibroblasts
engulf the apoptotic cells and subsequently release some
profibrogenic cytokines (like tumor growth factor beta,
TGF-β) and type I collagen, promoting the development
of fibrosis and cirrhosis (7).
There are 2 known pathways leading to apoptosis: the
first is a death receptor-mediated or extrinsic pathway,
and the second is an intrinsic pathway. The engaging of
one of the ligands (FasL, TRAIL, or TNF-α) to the death
receptors (Fas/CD95, TRAIL 1-2, or TNF R1), causes
some conformational changes, leading initially to the
activation of caspases 8 or 10. Subsequently, a proteolytic
cascade starts to activate caspases 3, 6, and 7 (the effector
caspases) via direct cleavage, or through the activation of
Bcl-2 family protein Bid makes mitochondrial dysfunction
to release cytochrome-c (caspase-activating factor) (1,9).
There is a growing interest in caspase cleavage of
cytokeratin proteins during apoptosis in all epithelial
tissues. Measurement of the cytokeratin fragments
cleaved by caspases (the most important cleavage caused
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by caspases 3 and 6) during apoptosis was found to be
a marker of ongoing apoptosis (10), and it is possible to
detect these cleavage cytokeratin fragments by sandwich
ELISA (11). M30- and M65-based ELISA detects such
cytokeratin fragments and all of the cytokeratin proteins
(both full-length and fragmented ones), respectively. M30based ELISA gives the amount of ongoing apoptosis, while
M65 shows the total cell death.
3. Importance of apoptosis in some selected liver
diseases
3.1. Acute liver failure
Acute liver failure (ALF) is associated with ongoing
massive hepatocyte death (1,4). While both apoptosis and
hepatic stellate cell activation were found to be upregulated
during the early phase of acute liver injury, Dechene et al.
investigated the amount of apoptosis and the degree of hepatic
stellate cell activation by using M30 and tissue inhibitor of
metalloproteinases (TIMP1 and 2) and hyaluronic acid
ELISA, and by immunohistochemical studies defining
caspase 3 and alpha smooth muscle (alpha SMA) as markers
of apoptosis and hepatic stellate cell activation in acute liver
failure patients (12). They found that both apoptotic cell
and hepatic stellate cell activation (fibrogenesis) markers
increase in ALF. By considering M30 to be a good marker
of underlying apoptotic process, Rutherford et al. described
a new index for predicting the survival rate of patients
presenting with ALF, and also showed that this new index,
combining clinical parameters and M30 level, had better
efficacy in predicting outcome compared with the King’s
College criteria and the Model for End Stage Liver Disease
(MELD) (13). On the other hand, an M65-based modified
MELD score had already been determined as a better scoring
system in predicting the lethal outcome in ALF patients than
the M30 (14). In contrast, Craig et al. suggested that none
of the cell death markers (M30 and M65) improved the
qualification of the existing scoring systems, particularly in
paracetamol-related ALF cases (15). Jochum et al. showed a
significant drop in M30 and M65 values at the end of 1 week
of therapy (16).
3.2. Nonalcoholic liver diseases
In contrast to ALF, the relation between chronic liver
injury and ongoing apoptosis has been known for years
(17). The presence of inflammation in the liver, with or
without fibrosis, is crucial in separating nonalcoholic
steatohepatitis (NASH), which indicates the possibility
of progressive liver injury, from simple hepatosteatosis.
Feldstein et al. showed increased TUNEL-positive cells
in the livers (apoptotic cells) of NASH patients compared
with a control group (2). Activated caspases 3 and 7, which
have important roles in the late phase of apoptosis, were
also detected in NASH patients. Moreover, the amount of
apoptotic cells was found to be correlated with the severity

of liver fibrosis (higher apoptosis in stage 3–4 fibrosis
than 1–2), and Fas staining scores were higher in NASH
patients than in the control, as expected. M30 level was
determined as an independent predictor of NASH in the
context of simple steatosis (18,19). However, Shen et al.
found that both M30 and M65 values in serum correlated
with histological progression in NASH patients, and
both increased in simple steatosis compared with healthy
controls, but they had a moderate impact on discriminating
NASH from simple steatosis (20).
3.3. Alcoholic liver diseases
While there are limited therapeutic options in severe acute
alcohol related liver disease (ASH), the use of early liver
transplantation has begun to be investigated (17). Natori et
al. revealed a higher amount of apoptosis by both TUNEL
and immunohistochemical detection of activated caspase
3 (21). Higher levels of serum bilirubin (>3 g/dL) and AST
(>75 U/L) were found to be correlated with a higher amount
of apoptotic cells, but not correlated with the survival of
ASH patients. Hepatic apoptosis was prominent in grade
4 steatohepatitis rather than grade 1 or 2 in ASH patients.
TNF-α expression was also noted in ASH patients, but
not in controls. In contrast to the NASH study mentioned
above, the expression of TNF-R1 was not upregulated in
ASH patients or controls; even TNF-α and FasR, which are
both death receptors, triggered apoptosis. FasL expression
was found to be high in alcohol-induced liver injury in
rats (22). Moreover, plasma TNF-α levels were higher in
ASH patients than controls (23). Gonzalez-Quintela et
al. showed that tissue polypeptide specific antigen, also a
keratin 18 fragment used as a tumor marker, has a positive
correlation with apoptotic score in ASH patients (24).
3.4. Chronic viral hepatitis
In active hepatitis C virus (HCV) infection, death receptorrelated apoptosis has already been shown to be a main
part of immune-mediated tissue damage, which presents
with viral antigens (9). The magnitude of apoptosis has
been shown to be related to fibrosis progression of chronic
HCV infection (25). Yılmaz et al. and Valva et al. showed
that there is a significant correlation between M30 level
and histological steatosis score in HCV patients (11,26).
More than half of the chronic HCV patients with normal
aminotransferases presented with higher M30 levels in
serum; although the importance of this is unknown, it may
perhaps be due to the underlying HCV-related steatosis in
the liver (25). On the other hand, Jazwinski et al. were not
able to determine any correlation between M30 levels and
the degree of steatosis in the liver of chronic HCV patients.
However, they were able to identify a positive correlation
between M30 level and the fibrosis stage (27). A human
trial with pan-caspase inhibitor IDN 6556 was shown to be
effective in reducing ALT levels in HCV-infected patients
and AST levels in NASH patients (28).
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Serum M30 levels were found to be significantly higher
in chronic hepatitis B virus (HBV) patients than inactive
HBV carriers, and Eren et al. determined similar M30
levels in serum in both inactive HBV carriers and healthy
controls (29,30). The usefulness of measuring serum M30
level in order to predict the grade of fibrosis or histological
activity index is still unknown. Joka et al. gave a cut-off
value for M30 sera level (240 U/L) to predict the presence
of chronic hepatitis B, and Papatheodorios et al. gave one
to establish the severity of underlying fibrosis (157.5 U/L)
(29,31).
3.5. Hepatocellular carcinoma
Dysregulated apoptosis (defective apoptosis, increased cell
proliferation) has an important role in hepatocarcinogenesis
(1). Not only hepatocellular carcinoma (HCC) but also
other epithelial-originated cancers (breast cancer and
head and neck cancer) and their risk of recurrence have
been shown to be correlated with the apoptosis index (32).
Most of the antitumoral treatments are targeted to a tumor
suppressor gene, p53. However, p53 is resistant against
some cancer drugs and can be overwhelmed by TRAIL
induction leading to TRAIL-mediated apoptosis (33).
Reduced Fas receptor expression is negatively correlated
with the survival of HCC patients (34). It has also been
shown that the M30 level is significantly higher in HCC
patients than control groups (35).
4. Antiapoptotic treatment strategy
It is uncertain as to whether improving the apoptosis rate
in the liver enhances ongoing inflammation and fibrosis.
The main caspase targeted for blocking the ongoing
apoptosis leading to liver injury is caspase 8 (9). Genetic
absence of caspase 8 attenuated liver injury in a mouse
experimental model (36). Wedemeyer et al. determined
that adiponectin, a hormone secreted from adipose tissue
reduced free fatty acid, induced CD95/FasR-mediated
apoptosis (37). Thus, an increase in the level of adiponectin
seems to be beneficial in patients with steatohepatitis.

Due its strong relation to TNF-α–mediated apoptosis
in alcoholic hepatitis, the anti-TNF-α agent infliximab was
already used in treatment (38). However, a discouraging
result arose. The rate of death (according to infection,
hemorrhage, and renal insufficiency) in the treatment
group was higher than in the placebo group and the study
had to be stopped.
It has been detected that p53, a tumor suppressor
gene, has some relations with apoptotic mechanisms, and
upregulates some death receptors (Fas, TRAIL-R1) and
their ligands (39). On the other hand, p53 has the ability
to engage BH-3-only proteins (proapoptotic proteins) and
Puma, Noxa, Bid, and Bax (BCL-2 homologues), leading
to the escape of damaged cells from apoptotic clearance.
A controversial point is the possible side effect of
antiapoptotic therapy resulting in cancer. Masuoka et al.
discussed this issue in a review article and concluded that
there is no carcinogenetic process induced by blocking
apoptosis by pan-caspases inhibitors as there are 2
pathways leading to apoptosis and with this therapy only
the death receptor-related apoptosis is prevented (9).
5. Conclusion
This article focused on the apoptosis of liver cells, not the
apoptosis of cancer cells or hepatic stellate cells. The latter
processes have quite different results. Cancer therapies are
mostly directly targeted at the apoptosis of cancer cells,
whereas the apoptosis of hepatic stellate cells is the main
issue to overcome in the fibrotic process. Recent studies
noted the importance of apoptosis in liver injury and
the possible ways to block the underlying dysregulated
apoptosis. However, it is still too early to suggest using
antiapoptotic agents in acute or chronic liver diseases
routinely. More experimental and clinical results are
needed to investigate the promising topic of apoptosis in
liver diseases.
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